Preneoplastic lesions and conditions of the urinary bladder

EAU Update Series

Volumn 1, Issue 2, 2003, Pages 53-63

  Montironi, Rodolfo ^a   Mazzucchelli, Roberta ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Carcinoma in situ; Dysplasia; Malignancy associated change; Urothelial hyperplasia; Urothelial papillary carcinoma; Urothelium

Indexed keywords

BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER GRADING; CANCER INVASION; CANCER MORTALITY; CANCER RESEARCH; CANCER RISK; CHROMOSOME 9; CHROMOSOME ABERRATION; CORRELATION ANALYSIS; CYTOLOGY; DISEASE ASSOCIATION; DISEASE COURSE; GENETIC ANALYSIS; GENETIC DISORDER; HEALTH CARE DELIVERY; HEALTH CARE SYSTEM; HISTOLOGY; HUMAN; KERATINIZATION; MEDICAL SOCIETY; MORPHOMETRICS; REVIEW; SQUAMOUS CELL METAPLASIA; STANDARDIZATION; STATISTICAL SIGNIFICANCE; UROGENITAL TRACT TUMOR; UROTHELIUM; WORLD HEALTH ORGANIZATION;

EID: 15744398205     PISSN: 15709124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1570-9124(03)00023-0     Document Type: Article

References (62)

1. Lopez-Beltran A, Cheng L, Anderson L, et al. Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation. Virchows Arch 2002;440:3-11.
2. Bostwick DG, Mikuz G. Urothelial papillary (exophytic) neoplasms. Virchows Arch 2002;441:109-16.
3. Busch C, Algaba F. The WHO/ISUP 1998 and WHO 1999 Systems for malignancy grading of bladder cancer. Scientific foundation and translation to one another and previous systems. Virchows Arch 2002;441:105-8.
4. Epstein JI, Amin MB, Reuter V, et al. The Bladder Consensus Conference Committee WHO/ISUP consensus classification of urothelial (transitional cell) lesions of the urinary bladder. Am J Surg Pathol 1998;22:1435-48.
5. Mostofi FK, Davis CI, Sesterhenn IA. Histological typing of urinary bladder tumours. World Health Organization, International Histological Classification of Tumours. 2nd ed. Berlin: Springer-Verlag; 1999.
6. Mostofi FK, Sorbin LH, Torloni H. Histological typing of urinary bladder tumours. International Classification of Tumours, 19. Geneva: World Health Organization; 1973.
7. Harnden P, Eardley I, Joyce AD, et al. Cytokeratin 20 as an objective marker of urothelial dysplasia. Br J Urol 1996;78:870-5.
8. Helpap B, Köllermann I. Assessment of basal cell status and proliferative patterns in flat and papillary urothelial lesions: a contribution of the new WHO classification of urothelial tumors of the urinary bladder. Hum Pathol 2000;31:745-50.
9. McKenney IK, Gomez IA, Desai S, et al. Morphological expressions of urothelial carcinoma in situ. A detailed evaluation of its histologic patterns with emphasis on carcinoma in situ with microinvasion. Am J Surg Pathol 2001;25:356-62.
10. Orozco RE, Martin AA, Murphy WM. Carcinoma in situ of the urinary bladder: clues to host involvement in human carcinogenesis. Cancer 1994;76:115-22.
11. Bostwick DG, Lopez-Beltran A. Bladder biopsy interpretation. New York: United Pathologists Press; 1999.
12. Bostwick DG, Ramnani D, Cheng L. Diagnosis and grading of bladder cancer and associated lesions. Urol Clin North Am 1999;26:493-507.
13. Baithun SI, Naase M, Blanes A, et al. Molecular and kinetic features of transitional cell carcinomas of the bladder: biological and clinical implications. Virchows Arch 2001;438:289-97.
14. Baud E, Catilina P, Boitux IP, et al. Human bladder cancers and normal bladder mucosa present the same hot spot of heterozygous chromosome-9 deletion. Int J Cancer 1998;77:821-4.
15. Hartmann A, Moser K, Kriegmair M, et al. Frequent genetic alterations in simple urothelial hyperplasia of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 1999;154:721-7.
16. Muto S, Horie S, Takahashi S, et al. Genetic and epigenetic alterations in normal epithelium in patients with metachronous bladder cancer. Cancer Res 2000;60:4021-5.
17. Czerniak B, Li L, Chaturvedi V, et al. Genetic modeling of human urinary bladder carcinogenesis. Genes Chrom Cancer 2000;27:392-402.
18. Hartmann A, Schlake G, Zaak D, et al. Occurrence of chromosome 9 and p53 alteration in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res 2002;62:809-18.
19. Standler WM, Steinberg G, Yang X, et al. Alterations of the 9p21 and 9q33 chromosomal bands in clinical bladder cancer specimens by fluorescence in situ hybridization. Clin Cancer Res 2001;7:1676-82.
20. Smith G, Elton RA, Beynon LL. Prognostic significance of biopsy results of normal looking mucosa in cases of superficial bladder cancer. Br J Urol 1983;55:665-9.
21. Montironi R, Longato Filho A, Santinelli A, et al. Nuclear changes in the normal-looking columnar epithelium adjacent to and distant from prostatic intraepithelial neoplasia and prostate cancer: morphometric analysis in whole-mount sections. Virchows Arch 2000;437:625-34.
22. McKenney JK, Desai S, Cohen C, et al. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium. An analysis of cytokeratin 20, p53, and CD44 antigens. Am J Surg Pathol 2001;25:1074-8.
23. Koss LG. Tumors of the urinary bladder. Atlas of tumor pathology, vol. 11 (second series). Washington (DC): AFIP; 1975.
24. Koss LG. Mapping of the urinary bladder: its impact on the concepts of the bladder cancer. Hum Pathol 1979;10:533-48.
25. Sarma KP. Genesis of papillary tumors: histological and microangiographic study. Br J Urol 1981;55:665-9.
26. Montironi R, Scarpelli M, Mazzucchelli R, et al. Subvisual chromatin changes are detected by karyometry in the histologically normal urothelium in patients with synchronous papillary carcinoma. Human Pathol (accepted for publcation).
27. Jones PA, Droller MJ. Pathway of development and progression in bladder cancer: new correlations between clinical observations and molecular mechanisms. Semin Urol 1993;11:177-92.
28. Bostwick DG, Ramnani D, Cheng L. Diagnosis and grading of bladder cancer and associated lesions. Urol Clin North Am 1999;26:493-507.
29. Lopez-Beltran A. Bladder treatment. Immunotherapy and chemotherapy. Urol Clin North Am 1999;26:535-54.
30. Kaubisch S, Lum BL, Reese J, et al. Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol 1991;146:28-31.
31. Takashi M, Sakata T, Murase T, et al. Grade 3 bladder cancer with lamina propria invasion -pT1-: characteristics of tumor and clinical course. Nagoya J Med Science 1991;53:1-8.
32. Thrasher JB, Frazier HA, Robertson JE, et al. Clinical variables that serve as predictors of cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 1994;73:1708-15.
33. Torti FM, Lum BL. Superficial bladder cancer: risk of recurrence and potential role for interferon therapy. Cancer 1987;59:613-20.
34. Malmstrom PU, Busch C, Norlen BJ. Recurrence progression and survival in bladder cancer. Scand J Urol Nephrol 1987;21:185-95.
35. Montironi R, Mazzucchelli R, Colanzi P, et al. Improving interobserver agreement and certainty level in diagnosing and grading papillary urothelial neoplasms. Usefulness of a Bayesian belief network. Eur Urol 2002;41:449-57.
36. Montironi R, Lopez-Beltran A, Mazzucchelli R, Bostwick DG. Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies. J Clin Pathol 2003;56:91-5.
37. Jarkrans T, Vasko J, Bentgsson E, et al. Grading of transitional cell bladder carcinoma by image analysis of histological sections. Anal Cell Pathol 1995;8:135-58.
38. Kruger S, Muller H. Correlation of morphometry, nucleolar organizer regions, proliferating cell nuclear antigen and Ki 67 antigen expression with grading and staging in urinary bladder carcinomas. Br J Urol 1995;75:480-4.
39. Mikuz G. The reliability and reproducibility of the different classifications of bladder cancer. In: Hauptmann S, Dietel M, Sobrinho-Simões M, editors. Surgical pathology update 2001, 18th European Congress of Pathology. Berlin: ABW Wissenschaftsverlag; 2001. p. 114-5.
40. Van Rhijn BWG, Montironi R, Zwarthoff EC, et al. Frequent FGFR3 mutations in urothelial papilloma. J Pathol 2002;198:245-51.
41. Chen L, Zhang S, Ulbright TM, et al. Genetic analysis of papillary urothelial neoplasm of low malignant potential of the urinary bladder using laser-assisted microdissection. Mod Pathol 2002;15:158A.
42. Samaratunga H, Makarov DV, Epstein JI. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelial neoplasms for risk of progression. Urology 2002;60:315-9.
43. Oosterhuis JWA, Schapers RFM, Janssen-Heijnen MLG, et al. Histologic grading of papillary urothelial carcinoma of the bladder: prognostic value of the 1998 WHO/ISUP classification system and comparison with conventional grading system. J Clin Path 2002;55:900-5.
44. Alsheikh A, Mohamedali Z, Jones E, et al. Comparison of the WHO-ISUP classification and cytokeratin 20 expression predicting the behavior of low grade papillary urothelial tumors. Mod Pathol 2001;14:267-72.
45. Cina SJ, Kristen J, Lancaster-Weiss KJ, et al. Correlation of Ki-67 and p53 with the New World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia. Arch Path Lab Med 2001;125:646-51.
46. Cheng L, Newman RM, Bostwick DG. Papillary urothelial neoplasms of low malignant potential. Am Cancer Soc 1999;86:2102-8.
47. Desai S, Lim SD, Jimenez RE, et al. Relationship of cytokeratin 20 and CD44 protein expression with WHO/ISUP grade in pTa and pT1 papillary urothelial neoplasia. Mod Pathol 2000;13:1315-23.
48. Holmang S, Andius P, Hedelin H, et al. Stage progression in Ta papillary urothelial tumours. Relationship to grade, immunohistochemical expression of tumor markers, mitotic frequency and DNA ploidy. J Urol 2001;165:1124-30.
49. Brandau S, Böhle A. Bladder cancer. I. Molecular and genetic basis of carcinogenesis. Eur Urol 2001;39:491-7.
50. Benson RC, Swanson SK, Farrow GM. Relationship of leucoplakia to urothelial malignancy. J Urol 1984;131:507-11.
51. Khafagy MM, El Bolkainy MN, Mansour MA. Carcinoma of the Bilharzial urinary bladder: a study of the associated mucosal lesions in 86 cases. Cancer 1972;30:150-9.
52. Ney C, Ehrlich JC. Squamous epithelium in the trigone of the human female urinary bladder with a note on cystoscopic observations during estrogen therapy. J Urol 1955;73:809-19.
53. Packham DA. The epithelial lining of the female trigone and urethra. Brit J Urol 1971;43:201-5.
54. Long ED, Shepherd RT. The incidence and significance of vaginal metaplasia of the bladder trogone in adult women. Br J Urol 1983;55:189-94.
55. Cifuentes L. Epithelium of vaginal type in the female trigone:the clinical problem of trigonitis. J Urol 1947;57:1028-37.
56. Elem B, Alam SZ. Total intestinal metaplasia with focal adenocarcinoma in a schistosoma-infested defunctioned urinary bladder. Br J Urol 1984;56:331-43.
57. Chan TY, Epstein JI. In situ adenocarcinoma of the bladder. Am J Surg Pathol 2001;25:892-9.
58. Corica FA, Husmann DA, Churchill BM, Young RH, Pacelli A, Lopez-Beltran A, et al. Intestinal metaplasia is not a strong risk factor for bladder cancer: study of 53 cases with long-term follow up. Urology 1997;50:427-31.
59. Shaw JL, Gislason GJ, Imbriglia JE. Transition of cystitis glandularis to primary adenocarcinoma of the bladder. J Urol 1958;79:815.
60. Cheng L, Cheville JC, Sebo TJ, Eble JN, Bostwick DG. Atypical nephrogenic metaplasia of the urinary tract: a precursor lesion? Cancer 2000;8:853-61.
61. Cheng L, Montironi R, Bostwick DG. Villous adenoma of the urinary tract:a report of 23 cases, including 8 with coexisting adenocarcinoma. Am J Surg Pathol 1999;23:764-71.
62. Young RH, Parkhurst EC. Mucinous adenocarcinoma of the bladder. Case associated with extensive intestinal metaplasia of the urothelium in a patient with nonfunctioning bladder for 12 years. Urology 1984;24:192-5.